{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:34:06Z","timestamp":1792708446281,"version":"4.5.0"},"reference-count":25,"publisher":"Massachusetts Medical Society","issue":"4","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2026,1,22]]},"DOI":"10.1056\/nejmoa2508959","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T22:00:26Z","timestamp":1769032826000},"page":"354-366","source":"Crossref","is-referenced-by-count":95,"title":["Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer"],"prefix":"10.1056","volume":"394","author":[{"given":"Sara M.","family":"Tolaney","sequence":"first","affiliation":[{"name":"Dana\u2013Farber Cancer Institute, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4509","authenticated-orcid":false,"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[{"name":"Institut Jules Bordet, H\u00f4pital Universitaire de Bruxelles and Universit\u00e9 Libre de Bruxelles, Brussels"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kalinsky","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherene","family":"Loi","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[{"name":"Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0809-0851","authenticated-orcid":false,"given":"Clinton","family":"Yam","sequence":"additional","affiliation":[{"name":"University of Texas M.D. Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Rapoport","sequence":"additional","affiliation":[{"name":"Medical Oncology Centre of Rosebank, Clinical and Translational Research Unit, Saxonwold, South Africa"},{"name":"Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-7199","authenticated-orcid":false,"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Mchayleh","sequence":"additional","affiliation":[{"name":"AdventHealth Cancer Institute, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Cescon","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Juntendo University Graduate School of Medicine, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Alejandro Lara","family":"Ba\u00f1uelas","sequence":"additional","affiliation":[{"name":"SCIENTIA Investigaci\u00f3n Cl\u00ednica, Chihuahua, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruffo","family":"Freitas-Junior","sequence":"additional","affiliation":[{"name":"Araujo Jorge Cancer Hospital, Goias Anticancer Association, Goi\u00e2nia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Salvador Bofill","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Afshari","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna","family":"Gary","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lai","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schmid","sequence":"additional","affiliation":[{"name":"Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","unstructured":"World Health Organization International Agency for Research on Cancer. Absolute numbers mortality females in 2022 (https:\/\/gco.iarc.fr\/today\/en\/dataviz\/pie?mode=cancer&group_populations=1&types=1&sexes=2&populations=900_903_904_905_908_909_935)."},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02309"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02864"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0"},{"key":"e_1_3_5_6_2","unstructured":"National Cancer Institute. Cancer stat facts: female breast cancer subtypes (https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html)."},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"e_1_3_5_10_2","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN guidelines) for breast cancer version 4. 2025 (https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf)."},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1021"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf034"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4318"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_5_15_2","unstructured":"BioPharma APAC. Singapore (HSA) approval marks the first in a series of expected approvals of Trodelvy in Asia. February 2022 (https:\/\/biopharmaapac.com\/news\/43\/1252\/-singapore-hsa-approval-marks-the-first-in-a-series-of-expected-approvals-of-trodelvy-in-asia.html)."},{"key":"e_1_3_5_16_2","unstructured":"European Medicines Agency. Trodelvy: summary of product characteristics (https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trodelvy-epar-product-information_en.pdf)."},{"key":"e_1_3_5_17_2","unstructured":"Chang M. Gilead\u2019s Trodelvy approved for metastatic triple-negative breast cancer in Korea. Korea Biomedical Review. May 2023 (https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=21060)."},{"key":"e_1_3_5_18_2","unstructured":"Pharmaceutical Technology. Everest\u2019s Trodelvy receives approval for breast cancer in China. June 10 2022 (https:\/\/www.pharmaceutical-technology.com\/news\/everest-trodelvy-breast-cancer\/)."},{"key":"e_1_3_5_19_2","unstructured":"Trodelvy (sacituzumab govitecan-hziy) prescribing information. Foster City CA: Gilead Sciences 2023 (https:\/\/www.trodelvyhcp.com\/-\/media\/project\/trodelvy\/trodelvyhcp\/hcp\/resource-pdf\/trodelvy_pi.pdf)."},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102395"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.801"},{"key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.esmoop.2024.103203","article-title":"Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: a phase Ib\/II study of multiple treatment (tx) combinations in pts with locally advanced\/metastatic BC (LA\/mBC).","volume":"9","author":"Schmid P","year":"2024","unstructured":"Schmid P, Loi S, De la Cruz Merino L, et al. Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: a phase Ib\/II study of multiple treatment (tx) combinations in pts with locally advanced\/metastatic BC (LA\/mBC). ESMO Open 2024;9:Suppl 4:1-47 (https:\/\/www.esmoopen.com\/article\/S2059-7029(24)00971-2\/fulltext).","journal-title":"ESMO Open"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01409"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511734"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2508959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T22:00:40Z","timestamp":1769032840000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2508959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,1,22]]}},"alternative-id":["10.1056\/NEJMoa2508959"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2508959","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}